#USA #Milford #Waters Corporation #BD Biosciences #FACSDiscover

Waters Corporation Launches the BD FACSDiscover A7 Cell Analyzer

Milford, MA, September 14, 2026 — Waters Corporation (NYSE: WAT) has officially launched the BD FACSDiscover™ A7 Cell Analyzer, a cutting-edge tool that transforms the landscape of flow cytometry. This state-of-the-art device not only combines exceptional sensitivity and spectral resolution but also introduces unprecedented ease-of-use features aimed at researchers in diverse settings, including academic institutions, pharmaceutical companies, and contract research organizations (CROs).

The BD FACSDiscover A7 Cell Analyzer expands the existing FACSDiscover platform, building on the advanced BD SpectralFX Technology integrated into its flagship predecessor, the BD FACSDiscover A8 Cell Analyzer. This new device stands out by enabling researchers to conduct experiments analyzing over 50 cell parameters simultaneously, all while maintaining a high quality of data consistency.

By utilizing the innovative FACSTruQ™ Technology, the analyzer offers a next-generation calibration system alongside automated setup and quality control features. This means researchers can expect an industry-leading standardization in their experiments, providing results that are reproducible across different instruments and users, with an impressive coefficient of variation below 10% when employing a palette of more than 50 fluorescent dyes. The FACSDiscover A7 streamlines the research process by integrating BD FACSChorus™ Software, which guides both novice and seasoned users through experimental workflows, enhancing speed and efficiency.

Cheryl Kim, Senior Director at the Flow Cytometry Core of the La Jolla Institute for Immunology, expressed optimism regarding this new tool. Kim stated, "The FACSDiscover A7 Cell Analyzer lowers the barrier to advanced spectral flow cytometry and will open up new possibilities for immunology research, enabling our core facility to help scientists uncover deeper biological insights with greater standardization and confidence."

Moreover, Steve Conly, Senior Vice President of Waters Biosciences, highlighted that this latest analyzer offers an impressive value, merging advanced spectral performance with a strong price-to-performance ratio. This makes spectral flow cytometry more accessible to a broader range of researchers focusing on critical applications, from biomarker discovery to drug development.

The launch of the FACSDiscover A7 Cell Analyzer is a significant milestone, occurring just two years after the first development of a 50-color flow cytometry panel on the BD FACSDiscover™ S8 Cell Sorter. This rapid advancement reflects the growing demands for reproducibility and reliability within research environments that rely heavily on sophisticated instrumentation.

Available for global distribution, interested parties can place orders through local representatives. For additional information and resources, visit waters.com and bdbiosciences.com/A7.

About Waters Corporation

Waters Corporation, listed on the NYSE under 'WAT', is a leading innovator in life sciences and diagnostics. The company dedicates itself to enhancing the pace of scientific discovery through cutting-edge analytical technologies, comprehensive informatics solutions, and unwavering customer service. Waters focuses on delivering high-quality products and services in regulated testing environments while collaborating globally to improve health outcomes and ensure safety across vital sectors such as pharmaceuticals and food analysis.

For further inquiries, please contact:
Molly Gluck
Head of External Communications
Waters Corporation
+1.508.498.9732
Email

Disclaimer: Becton, Dickinson and Company (BD) retains the legal manufacturing authority for Biosciences and Diagnostic Solutions products during the transfer of regulatory obligations to Waters Corporation. For specifics about this transition, detailed information can be found at waters.com/bdtransaction.